Can starting a new rescue inhaler in the ER keep asthma patients out of the hospital?
NCT ID NCT07166939
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving adults with acute asthma a specific rescue inhaler (Airsupra) right in the emergency department can reduce the chance of another asthma attack within 3 months. About 1,860 participants will either receive Airsupra or continue usual care. The goal is to see if early use of this inhaler leads to better asthma control and fewer urgent visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Airsupra (a combination inhaler for asthma rescue)
What this could lead to
If successful, this could show that starting Airsupra in the emergency department helps prevent asthma attacks and improves control after discharge.
What could go wrong
This is a phase 4 study, so Airsupra is already approved, but it may not significantly reduce asthma recurrence compared to usual care. Results depend on real-world adherence and may not apply to all asthma patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MetroHealth
RECRUITINGCleveland, Ohio, 44109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••